Press Release
Stockholm, Sweden, 28 May 2024
At the annual general meeting of Mendus AB (publ) (the "Company") on 17 May 2024 it was resolved on reverse share split of the Company's shares, whereby twenty (20) existing shares will be consolidated into one (1) new share. The board of directors was authorized to resolve on the record date for the reverse share split, wherein the board of directors has resolved that the record date for the reverse share split shall be 4 June 2024.
Reverse share split
To enable the reverse share split and otherwise adapt the limits of the articles of association for share capital and number of shares, the meeting also resolved to amend the limits of the share capital and number of shares in the articles of association. The Swedish Companies Registration Office has registered these resolutions and the board of directors has now resolved that the record date for the reverse share split shall be 4 June 2024.
The Company's shareholders do not need to take any measures to participate in the reverse share split. Shareholders will automatically receive a new, lower, number of shares in proportion to their holding on the record date on 4 June 2024. Shareholders whose holding of shares on the record date is not evenly divisible with the consolidation quota twenty will receive shares free of charge from Aktieinvest Fondkommission AB for the holding to be evenly divisible by twenty.
Through the reverse share split, the number of shares in the Company decreases from 1,007,191,573 to 50,359,578. Further, the reverse share split entails that the share's quota value will increase from SEK 0.05 to SEK 1,00.
As a result of the reverse share split, the ISIN code of the Company's share will change. As of 3 June 2024, the share will trade with the new ISIN code SE0022239950.
Timetable
The following timetable applies for the reverse share split.
| Date | Measure |
| 31 May 2024 | Last day of trading in the Company's share before the reverse share split. |
| 3 June 2024 | First day of trading in the Company's share after the reverse share split. As of this date, the share price reflects the effect of the reverse share split and the Company's share will trade with the new ISIN code SE0022239950. |
| 4 June 2024 | Record date for the reverse share split. |
| 5 June 2024 | The new number of shares is expected to be registered in each shareholder's securities account. |
For more information, please contact:
Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com
About Mendus AB (publ)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. https://www.mendus.com/
